NYSE · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · LARGE CAP
Trulieve Cannabis Corp. TRLV
7 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$1.2B
▼ 0.4% vs FY2024
EPS · FY25
$-0.58
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-10.3%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 1.2B
Revenue, FY2025 · full 7-year series below
Revenue
Net income
The company lost 10 cents on every revenue dollar this year.
Per share
USD -0.58
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin12.1%
Net margin-10.3%
Return on assets-4.4%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+17.8% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−1.0%
+17.8%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.19B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 2.7B
total assets, end of FY2025
Total assetsUSD 2.7B
CashUSD 255.5M
Gross debtUSD 136.7M
Net debtUSD -118.8M
Current ratio4.43×
History
7 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
Revenue $B
1.2
1.2
1.1
1.2
0.9
0.5
0.3
Operating income $B
0.1
0.1
−0.2
0.1
0.2
0.2
0.1
EBITDA $B
·
·
·
0.1
0.2
0.2
0.1
Income tax $B
0.2
0.2
0.2
0.2
0.1
0.1
0.1
Net income $B
−0.1
−0.2
−0.5
−0.3
0.0
0.1
0.1
EPS, diluted $
−0.58
−0.79
−2.28
−0.95
0.21
0.53
0.46
Dividend / sh $
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
·
Shares out B
0.19
0.19
0.19
0.19
0.18
0.12
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
22 of 26
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 2 failures and 2 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed